| 李永红 毕华 陈伟 饶春明.动态光散射法测定病毒载体基因治疗产品的平均粒径及粒径分布[J].现代生物医学进展英文版,2014,14(34):6611-6613. |
| 动态光散射法测定病毒载体基因治疗产品的平均粒径及粒径分布 |
| Measurement of Particle Size and Distribution of Viral Vector Gene TherapyProducts Using Dynamic Light Scattering (DLS) |
| |
| DOI： |
| 中文关键词: 动态光散射 粒径 粒径分布 病毒载体基因治疗产品 质量控制 |
| 英文关键词: Dynamic light scattering Size Size distribution Viral vector gene therapy products Quality control |
| 基金项目:国家高技术研究发展（863）计划（2012AA020805）；国家科技重大专项（2012ZX09304010） |
|
| Hits: 752 |
| Download times: 1833 |
| 中文摘要: |
| 目的：建立病毒载体基因产品的粒径及分布的测定方法。方法：采用马尔文Zetasizer Nano ZS 型纳米粒度仪，以氯化钠注
射液作为稀释剂对样品进行适当稀释后，用手动测量方式进行测定。结果：测定的60 nm标准纳米粒子平均粒径为61.24± 0.68
nm，多分散指数（polydispersity index, PDI）为0.020± 0.012 nm。重组人新型P53 腺病毒注射液测定6 次，平均粒径为122.42±
1.80 nm，相对标准偏差（RSD）为1.4%；PDI值为0.056± 0.014 nm，RSD 为25.1%。重组人新型P53 腺病毒注射液于37℃存放时，
平均粒径和PDI值随时间延长有显著增加。至28 天时，平均粒径增加到130.50，PDI值增加到0.265。结论：动态光散射法快速、简
便、准确，可用于病毒载体基因治疗产品的粒径及分布的检测。 |
| 英文摘要: |
| Objective:To establish the method to measure particle size and distribution of viral vector gene therapy products.Methods:The size and distribution were measured by Nano Particle Analyzer (Malvern Zetasizer Nano ZS) using sodium chloride
injection as diluting agent, and manual operation mode was adopted.Results:The measurement result of the 60nm nanosphere size
standard showed that the z-average diameter was 61.24± 0.68 nm, and the polydispersity index (PDI) was 0.020± 0.012. After measured
by 6 times the z-average diameter result of the new type of recombinant human P53-adenovirus (new P53-Adv) injection was 122.42±
1.80 nm, and relative standard derivation (RSD) was 1.4%. The PDI value of the new P53-Adv injection was 0.056± 0.014, and relative
standard derivation (RSD) was 25.1%. When the new P53-Adv injections were stored at 37℃ , the z-average diameter and PDI value
increased with the incubation time. After incubation of 28 days the z-average diameter increased to130.50 nm, and the PDI increased to
0.265.Conclusion:The dynamic light scattering method which is fast, simple and accurate, can be used to measure the particle size and
distribution of viral vector gene therapy products. |
|
View Full Text
View/Add Comment Download reader |
| Close |
